Farmacocinética de la cefalona (cqmpca) en vacas, una nueva serie de antimicrobianos

Abstract

PHARMACOKINETIC VARIABLES OF A NEW ANTIBACTERIAL AGENT CALLED CEFALONE (CQMPCA), WORLDWIDE PATENTED, WERE ESTABLISHED IN HOLSTEIN COWS IN MEXICO. TWENTY FOUR HOLSTEIN COWS WERE DIVIDED INTO FOUR GROUPS OF SIX ANIMALS EACH AS FOLLOWS: GROUP 1, RECEIVING 10 MG/KG OF CQMPCA IN A SINGLE IV BOLUS INJECTION; GROUP 2 THE SAME DOSE BUT INJECTED IM; GROUP 3 RECEIVING 5 MG/KG OF CQMPCA IN A SINGLE IV BOLUS INJECTION, AND GROUP 4 AS FOR GROUP 2 BUT AT 5 MG/KG. BLOOD SAMPLES FROM ALL ANIMALS WERE OBTAINED WITH A CATHETER IMPLANTED IN THE JUGULAR VEIN, AT DIFFERENT TIMES FOR 8 HOURS. ANALYTICAL TECHNIQUES TO QUANTIFY CQMPCA INCLUDED UV-VISIBLE SPECTROPHOTOMETRY AND HIGH PRESSURE LIQUID CHROMATOGRAPHY (HPLC). PLASMA CONCENTRATION VS. TIME RELATIONSHIP IN ALL FOUR GROUPS WERE BEST DESCRIBED BY A TWO COMPARTMENT OPEN MODEL. CORRELATION BETWEEN B ANGLES IN ALL FOUR GROUPS SUGGESTED THAT USING THE DOSE RANGES SPECIFIED ABOVE, THE DRUG WOULD FOLLOW A FIRST ORDER KINETICS. AN 84% BIOAVAILABILITY WAS CALCULATED AFTER THE IM INJECTION OF THE DRUG, AND A MAXIMAL PLASMA CONCENTRATION AFTER THE IM INJECTION OF I.57 MG/ML AFTER 2.6 H FROM THE INJECTION. APPARENT VOLUME OF DISTRIBUTION (VDAREA) WAS SET AT 2.86L/KG AND A HALF LIFE OF THE POST-DISTRIBUTION PHASE OF 3.58 H. BASED ON THESE RESULTS, IT IS CONCLUDED THAT CQMPCA POSSESSES SUITUABLE CHARACTERISTIC SIMILAR TO THIRD GENERATION CEPHALOSPORINS WHICH INCLUDED HIGH TISSUE DISTRIBUTION AND RELATIVELY SLOW BODY CLEARANCE. THESE PHARMACOKINETIC FEATURES AND PREVIOUS REFERENCES OF POTENT IN VITRO ANTIBACTERIAL ACTIVITY SUGGEST EXCELLENT CLINICAL EFFICACY. IT IS SUGGESTED THAT MORE STUDIES SHOULD BE FOLLOWED.